AAV with Enh358MCK promoter driven EGFP-T2A-CreERT2

This AAV expresses EGFP-T2A-CreERT2 driven by a muscle Enh358MCK promoter.

Muscle creatine kinase (MCK) is highly active in all striated muscles. MCK is the most abundant non-mitochondrial mRNA that is expressed in all skeletal muscle fiber types and is also highly active in cardiac muscle. The main regulatory regions in the murine MCK gene include a 358 bp proximal promoter and a muscle-specific, 200bp enhancer located approximately 1.1 kb away from the transcription start site. The muscle-specific enhancer contains 2 copies of E-Boxes, which are believed to be critical for the enhancer activity. Enh358MCK (Enh stands for enhancer, and 358MCK stands for the 358bp MCK proximal promoter) is constructed by ligating the ~200bp enhancer with the 358 bp proximal promoter of the murine MCK gene. This artificial promoter of about 0.6 Kb displays more or less the same activity as that of the full length 1.3 Kb MCKpromoter.

The short 2A peptide sequences, when cloned in-frame between two genes, allow for efficient, stoichiometric production of discrete protein products within a single vector through a novel "cleavage" event within the 2A peptide sequence. This differs from conventional approaches for multiple protein expressions, such as IRES-mediated bicistronic gene expression, which has several limitations including imbalanced protein expression. The use of 2A peptide sequences alleviates these concerns, since 2A-mediated "self-cleavage" gives rise to a 1:1 ratio of the two separate proteins. Several forms of 2A peptide are commonly used: T2A (Thoseaasigna virus 2A), P2A (porcine teschovirus-1 2A), E2A (equine rhinitis A virus), and F2A (foot-and-mouth disease virus, FMDV 2A).

A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as "inducible Cre"). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.